Editas Medicine pricing shares at $16 for year's first IPO: reports

Editas Medicine Inc. EDIT, +0.00% priced shares for its initial public offering at the low end of the range, according to media reports late Tuesday, for what will be 2016’s first IPO. Editas will price 5.9 million shares at $16 a share, at the low end of its $16 to $18 range, to raise $94.4 million. That give Editas a market valuation of $571 million, according to Reuters. Cambridge, Mass.-based Editas develops treatments for genetic-based diseases via editing gene sequences.
Most Recent Posts:
Mass Eye and Ear Scientist Identifies Molecule Unlocking Glaucoma
Potential Cure May Impact Other Neurodegenerative Disease Therapies There is no cure (yet). Glaucoma often robs…
First Brigham Ignite Awards of the Year Announced
The Two Projects Focus on Robotic AI-Guided Intubation and Gamma Delta T Cell Therapy for Solid Tumors…